Pharmaceutical

Arcus Biosciences obtains loan facility with Hercules Capital worth $250m

Arcus turned to Hercules Capital’s financing for support and to advance its HIF-2α inhibitor casdatifan.

Aug 29, 2024 - 04:00
Arcus Biosciences obtains loan facility with Hercules Capital worth $250m
Arcus turned to Hercules Capital’s financing for support and to advance its HIF-2α inhibitor casdatifan.
Read the original article

Tags:

Previous Article

Bayer teams up with lncRNA-focused NextRNA in $547m deal

Next Article

Soleno wins FDA priority review for Prader-Willi therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: How the government can help lower the price — not just the cost — of cutting-edge gene therapies

Opinion: How the government can help lower the price — ...

Nov 1, 2023

STAT+: J&J agrees not to enforce patents on a key tuberculosis drug in dozens of poor countries

STAT+: J&J agrees not to enforce patents on a key tuber...

Sep 30, 2023

Santhera’s Agamree becomes first approved treatment in UK for all DMD patients

Santhera’s Agamree becomes first approved treatment in ...

Jan 13, 2024